Search - tctmd.com

Displaying 521 - 540 of 1325

Sort: Relevancy | Date

News Conference News TCT 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

L.A. McKeown

November 02, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Four

Shelley Wood

November 02, 2017

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

News Conference News TCT 2017

VAMPIRE 3: Attenuated Plaque May Signal Benefit of Thrombus Removal in PCI

Shelley Wood

November 01, 2017

REVASCTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

News Conference News TCT 2017

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

Todd Neale

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

Shelley Wood

October 30, 2017

News Conference News TCT 2017

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

Yael L. Maxwell

October 30, 2017

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

News Daily News

Short-term Changes in Exercise Habits Can Alter Long-term Prognosis of Stable CAD Patients

Caitlin E. Cox

October 26, 2017

News Opinion Fellow Talk

My Picks for Fellows Attending TCT 2017

Amit K. Gupta, MBBS, MD

October 26, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

Study Links Marijuana Use to Hypertension-Related Death

Ashley Lyles

August 10, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

Advertisement

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

Live From Denver: TCT 2017, Day Four

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

VAMPIRE 3: Attenuated Plaque May Signal Benefit of Thrombus Removal in PCI

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

Live From Denver: TCT 2017, Day One

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Short-term Changes in Exercise Habits Can Alter Long-term Prognosis of Stable CAD Patients

My Picks for Fellows Attending TCT 2017

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Study Links Marijuana Use to Hypertension-Related Death

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content